A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Advanced Cervical Cancer Clinical Trial

Official title:
Phase I Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

Status Recruiting

Clinical Trial Summary

A phase I clinical trial of tolerability and pharmacokinetics of TQB2858 injection in subjects with advanced malignancy.

n/a

NCT number	NCT05068921
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Beihua Kong, Doctor
Phone	18560081888
Email	kongbeihua@sdu.edu.cn
Status	Recruiting
Phase	Phase 1
Start date	December 9, 2021
Completion date	July 2023

See also
Status	Clinical Trial	Phase
Completed	`NCT01088347` - Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer	Phase 1/Phase 2
Completed	`NCT04590599` - A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy	Phase 2
Terminated	`NCT02853604` - Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer	Phase 3
Recruiting	`NCT04731038` - Combination Therapy for First Line Treatment of Advanced Cervical Cancer	Phase 1
Recruiting	`NCT04508686` - Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)	Phase 1
Completed	`NCT02888717` - Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers	N/A